Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 · New England Journal of Medicine · 11K citations
https://doi.org/10.1056/nejm200103153441101
J
José Baselga
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
368
Papers
74.2K
Citations
109
h-index
243
i10-index
José Baselga is an academic researcher from Weatherford College. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 109, co-authored 313 publications.
Papers by this author
worksTrastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 · New England Journal of Medicine · 3,715 citations
https://doi.org/10.1056/nejmoa1209124
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 · New England Journal of Medicine · 2,495 citations
https://doi.org/10.1056/nejmoa1113216
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
2017 · New England Journal of Medicine · 1,370 citations
https://doi.org/10.1056/nejmoa1703643
The EGF receptor family as targets for cancer therapy
2000 · Oncogene · 1,342 citations
https://doi.org/10.1038/sj.onc.1204082
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
2010 · The Lancet · 1,244 citations
https://doi.org/10.1016/s0140-6736(09)61964-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat